机译:尿激酶型纤溶酶原激活剂及其在甲状腺肿瘤中的抑制剂:细胞溶胶研究
Clinical Department of Nuclear Medicine and Radiation Protection Clinical Hospital Centre Zagreb;
Department of Medical Oncology Clinical Hospital Centre Zagreb;
Department of Diagnostic and Interventional Radiology Clinical Hospital Centre Zagreb;
Clinical Department of Nuclear Medicine and Radiation Protection Clinical Hospital Centre Zagreb;
Clinical Department of Nuclear Medicine and Radiation Protection Clinical Hospital Centre Zagreb;
Department of Pathophysiology Clinical Hospital Centre Zagreb;
Urokinase-type plasminogen activator; Type 1 plasminogen activator inhibitor; Thyroid cancer; Prognosis; Enzyme-linked immunosorbent assay;
机译:黑色素瘤和良性皮肤色素瘤中的组织和尿激酶型纤溶酶原激活物和1型纤溶酶原激活物抑制剂。
机译:尿激酶型纤溶酶原激活物,纤溶酶原激活物抑制剂-1和尿激酶型纤溶酶原激活物受体的乳头抽吸液表达可预测乳腺癌的诊断和晚期疾病。
机译:尿激酶型纤溶酶原激活物,尿激酶型纤溶酶原激活物受体和纤溶酶原激活物抑制剂-1和-2在肝细胞癌中的表达。
机译:抑制肿瘤相关的尿激酶型纤溶酶原激活系统:高水平合成在体外和体内卵巢癌细胞中可溶性尿激酶受体的影响
机译:巨噬细胞和尿激酶型纤溶酶原激活物在骨骼肌肥大中的作用。
机译:尿激酶型纤溶酶原激活剂(uPA)及其抑制剂(PAI-1)对892例乳腺癌患者的细胞质和颗粒提取物的预后影响
机译:尿激酶型纤溶酶原激活剂(uPA)及其抑制剂(PAI-1)对892例乳腺癌患者的细胞质和颗粒提取物的预后影响